GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have recei ...

EMA encourages NAMs to replace animal testing, aligning with 3Rs principles, and has published a concept paper on regulatory ...

Under terms of the deal, Bavarian Nordic shareholders will receive an all-cash offer at a premium, with plans to delist the ...

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Trump says spoke to Thai, Cambodia leaders after ceasefire Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, ...

The Italian Customs and Monopolies Agency launches the #SoCosaPorto campaign, an initiative that provides travelers with ...

A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

BeOne Medicines AG (NASDAQ:ONC) saw its stock rise 2.5% in pre-market trading after the European Medicines Agency (EMA) issued a favorable opinion on its cancer drug TEVIMBRA for early-stage lung ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

"Tevimbra is already approved in the EU across multiple settings in [non-small cell lung cancer], the most common form of lung cancer, and this positive CHMP opinion expands its potential to help ...

Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological respon ...